Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
0.0152
+0.0001 (0.66%)
Jul 31 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.02
52 week 0.01 - 0.13
Open 0.01
Vol / Avg. 91,430.00/341,581.00
Mkt cap 1.82M
P/E     -
Div/yield     -
EPS -0.03
Shares 117.50M
Beta 35.12
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -808.38% -2214.83%
Return on average equity - -
Employees 3 -
CDP Score - -

Address

469 Jean-Talon West, 3rd Floor
MONTREAL, QC H3N 1R4
Canada
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links

Description

Sunshine Biopharma, Inc. is a pharmaceutical company. The Company focuses on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound is Adva-27a, which is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. Adva-27a is a Topoisomerase II inhibitor. The Company's drug Adva-27a is used against various multidrug resistant cancer cells: Breast Cancer Cells (MCF-7/MDR), Small Cell Lung Cancer Cells (H69AR), Uterine Cancer (MES-SA/Dx5) and Pancreatic Cancer (Panc-1). Adva-27a has a clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 62
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 54
Abderrazzak Merzouki Chief Operating Officer, Director
Age: 51